Madrigal Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MDGL Madrigal Pharmaceuticals Inc
FPAY FlexShopper Inc
TCS Container Store Group Inc
CMSA CMS Energy Corp
LULU Lululemon Athletica Inc
MGY Magnolia Oil & Gas Corp
LGHL Lion Group Holding Ltd
C Citigroup Inc
SYBX Synlogic Inc
MDBH Public Ventures LLC
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

Closing Price
$153.34
Day's Change
-6.17 (-3.87%)
Bid
--
Ask
--
B/A Size
--
Day's High
161.72
Day's Low
151.42
Volume
(Light)
Volume:
393,502

10-day average volume:
586,913
393,502
Historical quotes & splits

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
27.35x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

August 2023
Current Month
2.0M
Previous Month
1.8M
Percent of Float
12.00%
Days to Cover
10.1089 Days

Share Information

MDGL is in a share class of common stock
Float
16.3M
Shares Outstanding
18.5M
Institutions Holding Shares
283
% Held by Institutions

% Held by Institutions

Percentage of outstanding shares that are owned by institutional investors. Calculated from current quarterly filing as of today.

91.10%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Julian C. Baker
  • Bill SiboldPres.
  • Alex G. HowarthCFO
  • Rebecca A. TaubCorp.Exec.
  • Brian J. LynchSr.VP

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.

3rd Party Research Disclosure